These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19624460)

  • 1. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency.
    Schmid P; Brodmann D; Odermatt Y; Fischer AG; Wuillemin WA
    J Thromb Haemost; 2009 Oct; 7(10):1629-32. PubMed ID: 19624460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function.
    Schmid P; Brodmann D; Fischer AG; Wuillemin WA
    J Thromb Haemost; 2009 Apr; 7(4):552-8. PubMed ID: 19175499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
    Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
    Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.
    Damle B; Jen F; Sherman N; Jani D; Sweeney K
    J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.
    Stöbe J; Siegemund A; Achenbach H; Preiss C; Preiss R
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):455-65. PubMed ID: 17063975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective observational cohort study of bioaccumulation of dalteparin at a prophylactic dose in patients with peritoneal dialysis.
    Schmid P; Brodmann D; Fischer AG; Wuillemin WA
    J Thromb Haemost; 2010 Apr; 8(4):850-2. PubMed ID: 20088934
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of dalteparin during haemodialysis.
    Nigten J; de Groot KA; Grootendorst DC; Koolen SL; Herruer MH; Schut NH
    Nephron Clin Pract; 2013; 124(3-4):179-83. PubMed ID: 24401673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No effect of norepinephrine dose on anti-Xa activity in critically ill patients
.
    Meenks SD; Foudraine NA; Broen K; le Noble JLML; Janssen PKC
    Int J Clin Pharmacol Ther; 2020 Apr; 58(4):223-229. PubMed ID: 32000886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
    Verhave G; Weijmer MC; van Jaarsveld BC
    Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
    Kani C; Markantonis SL; Nicolaou C; Maggina N
    J Crit Care; 2006 Mar; 21(1):79-84. PubMed ID: 16616629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.
    Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM
    Crit Care; 2006; 10(3):R93. PubMed ID: 16790078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring.
    van Bergen EDP; Huisman A; Welsing PMJ; de Winter MA; Rookmaaker MB; Kaasjager HAH; Nijkeuter M
    Neth J Med; 2019 Dec; 77(10):360-365. PubMed ID: 31880268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the low molecular weight heparin dalteparin in cats.
    Mischke R; Schmitt J; Wolken S; Böhm C; Wolf P; Kietzmann M
    Vet J; 2012 Jun; 192(3):299-303. PubMed ID: 21978598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses.
    Schwarzwald CC; Feige K; Wunderli-Allenspach H; Braun U
    Am J Vet Res; 2002 Jun; 63(6):868-73. PubMed ID: 12061534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.